CTLA4-Ig (Abatacept) for Prevention of Type 1 Diabetes in Relatives At-Risk
This study is for:
TrialNet Pathway to Prevention Study participants who have two or more antibodies other than insulin autoantibody
About this study
Abatacept is used to treat rheumatoid arthritis and other autoimmune diseases. In 2011, the TrialNet consortium showed that it preserved pancreas function in people with recently-diagnosed T1D (link to Lancet 2011; 378: 412–19). We are now testing whether Abatacept also preserves pancreas function earlier in the course of T1D.
This is a randomised controlled trial, meaning one half of the participants are randomly allocated to receive Abatacept and the other half to placebo (dummy treatment). Participation involves 13 monthly infusions at a research unit followed by 6-monthly follow-up visits.
This trial is running in Adelaide and Melbourne.
For more information about this study